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Mass spectrometry, and especially electrospray ionization, is now an efficient tool to study
noncovalent interactions between proteins and inhibitors. It is used here to study the
interaction of some weak inhibitors with the NCoA-1/STAT6 protein with KD values in the M
range. High signal intensities corresponding to some nonspecific electrostatic interactions
between NCoA-1 and the oppositely charged inhibitors were observed by nanoelectrospray
mass spectrometry, due to the use of high ligand concentrations. Diverse strategies have
already been developed to deal with nonspecific interactions, such as controlled dissociation
in the gas phase, mathematical modeling, or the use of a reference protein to monitor the
appearance of nonspecific complexes. We demonstrate here that this last methodology,
validated only in the case of neutral sugar–protein interactions, i.e., where dipole–dipole
interactions are crucial, is not relevant in the case of strong electrostatic interactions. Thus, we
developed a novel strategy based on half-maximal inhibitory concentration (IC50) measure-
ments in a competitive assay with readout by nanoelectrospray mass spectrometry. IC50 values
determined by MS were finally converted into dissociation constants that showed very good
agreement with values determined in the liquid phase using a fluorescence polarization
assay. (J Am Soc Mass Spectrom 2009, 20, 303–311) © 2009 Published by Elsevier Inc. on
behalf of American Society for Mass Spectrometry
There is a strong interest in the study of noncova-lent complexes between biomolecules, which areplaying key roles in life. Numerous solution-
phase analytical techniques were developed to deter-
mine the specificity and the strength of these types of
interactions [1]. Mass spectrometry (MS), and especially
electrospray ionization (ESI) [2], has become an efficient
tool to study specific noncovalent complexes between
various species (protein–protein, protein–small mole-
cules, protein–DNA, DNA–DNA . . .) [3–8]. In fact, ESI
is a very soft ionization technique, i.e., noncovalent
complexes can be transferred intact from solution into
the gas phase. Quantitative information such as stoichi-
ometry, binding constants, or reaction kinetics can be
obtained by ESI-MS, and values are often in good
agreement with data coming from well-established so-
lution phase techniques. Nevertheless, the study of
noncovalent [protein–ligand] complexes require careful
control of experimental parameters. Buffer, pH, pres-
sure, and voltages applied to the different stages of the
mass spectrometer have great influence on spectral
characteristics and on the information gained. Moreover,
electrochemical reactions and desolvation/ionization
mechanisms involved in ESI can also complicate the
analysis, thus giving rise to the so-called nonspecific
interactions (i.e., interactions with nonspecific binding
sites) that alter the solution phase stoichiometry. To
study weak complexes with dissociation constants (KD)
in the M range or higher in solution, high ligand
concentrations are employed, leading to an increase of
nonspecific complex ions signals and to underestimate
KD values, which might not reflect the solution-phase
equilibria anymore [5, 9–16].
Three strategies have been developed to determine
affinities of weak [protein–ligand] complexes by ESI-
MS, even when nonspecific gas-phase interactions un-
settle the analysis.
1. One possibility is to disrupt the nonspecific gas-
phase interactions between ligand and protein by
using blackbody infrared radiation dissociation
(BIRD) [12]. Nonetheless, it was shown that in some
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cases nonspecific interactions can be even stronger
than the specific interactions, leading to the destruc-
tion of the complex of interest [5].
2. Daubenfeld et al. have shown that specific ligand
binding is modeled as a binomial distribution, while
complexes resulting from nonspecific gas-phase in-
teractions follow a statistical Poisson distribution
[15]. As a consequence, the contributions of specific
and nonspecific binding on the mass peak distribu-
tions could be modeled from the dependence on
ligand concentration. This method has been success-
fully used to determine the affinity range of ADP
and ATP binding with creatine kinase. However,
since many numerical parameters of the model have
to be adjusted, high quality spectra are required,
and initial knowledge of the specific interactions is
required.
3. Klassen et al. [16] reported a third strategy: a refer-
ence protein that is known to not specifically bind
with the ligand in solution phase is added to the
sample mixture consisting of the ligand and the
target protein. Detection of noncovalent complexes
between the ligand and the reference protein by
nanoESI-MS results only from gas-phase interac-
tions. Peak intensities and their distribution could
be used to model gas-phase interactions between the
ligand and the target protein. The principal assump-
tion that the fraction of proteins and protein com-
plexes that engage in nonspecific ligand binding
during the nanoES process is determined by the
number of free ligand molecules in the offspring
droplets leading to gaseous ions and is independent
of the size and structure of the protein or protein
complex.
Considering the key role of MS in the drug discovery
process, we focused on the development of new ESI
assays, which could be of value to measure the affinity
of noncovalent [protein–peptide] complexes, even if
these exhibit some nonspecific interactions in the gas
phase. As an example of the methodology, we explore
the binding of some cyclopeptides with the PAS-B
domain of the co-activator protein NCoA-1, also called
steroid receptor coactivator-1 (SRC-1). NCoA-1 is one of
the essential proteins involved in the interleukin-4/
interleukin-13 (IL4/IL13) signaling cascade, which con-
trols the activation of genes implicated in immune and
anti-inflammatory responses [17, 18]. The ability of IL-4
to affect cellular differentiation requires the activation
of the signal transducer and activator of transcription 6
(STAT6). Following binding of IL-4/IL-13 to the extra-
cellular domain of the IL-4/13 receptor, IL-4 becomes
phosphorylated, whereupon it dimerizes through non-
covalent interactions, translocates to the nucleus, and
there binds through its DNA-binding domain to the
transcriptional start regions of IL-4/IL-13 responsive
genes. A short C-terminal segment of STAT6, called
the transactivation domain, recruits components of the
transcriptional machinery to activate transcription. One
of these components is the coactivator protein NCoA-1
[19]. It has been proposed that blocking the binding of
STAT6 and NCoA-1 are potentially of therapeutic inter-
est for the treatment of allergic reactions, including
asthma and atopic diseases [20, 21]. In the following, we
propose to use a reference peptide with a known KD
value for the NCoA-1 PAS-B domain. Displacement of
the reference peptide from the protein by an inhibitor
leads to a decrease in the peak intensity of the reference
protein–peptide complex. As internal standard, a sec-
ond protein, i.e., myoglobin, has been chosen to bind
with neither the reference peptide nor the inhibitor in
solution or in the gas phase. After normalization, data
are fitted to a sigmoid equation to determine the IC50
values from the dependence on inhibitor concentration.
Thereafter, KD values of the competitive inhibitors are
extrapolated using a general Cheng-Prusoff equation.
Material and Methods
Chemicals
Commercial reagents were used without further pu-
rification. Myoglobin, lysozyme, lactalbumin, ammo-
nium bicarbonate, methanol, and acetic acid were
purchased from Sigma-Aldrich Chemie GmbH (Buchs,
Switzerland).
Peptide Synthesis
Peptides 1, 2, and 6, and inhibitors A, B, and C (Table 1)
were synthesized by solid-phase methods using stan-
dard Fmoc chemistry on an Applied Biosystems (Rot-
kreuz, Switzerland) 433A peptide synthesizer. The
backbone-cyclic peptides were assembled on 2-chloro-
Table 1. Monoisotopic masses and KD values obtained by fluorescence polarization assay and by mass spectrometry for the STAT6-
derived peptides
Sequences
Monoisotopic
mass (Da)
KI obtained by fluorescence
polarization assay (M) [22]
KI obtained
here (M)
(1) LLPPTEQDLTKLLLEGQGESGY 2400.2 0.26 0.30
(2) LPPTEQDLTKLLLEGQGESGY 2287.2 7.5 Used as reference
Inhibitor A: cyclic-FEWLGWEFpP 1288.5 3.0 2.2
Inhibitor B: cyclic-FEWLAREFpP 1272.6 20 20
Inhibitor C: cyclic-FEWLLWEFpP 1318.5 12.1 5.6
(6) Ac-GTWIGEDIFPPLLPPTEQDLTKLLLEGQGESG 3491.2 0.040 0.017
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trityl chloride resin (Novabiochem). The synthesis of
peptide 1 is described here as a typical procedure.
Fmoc-Tyr-OH (0.25 mmol) was coupled to 2-
chlorotritylchloride resin (600 mg, loading  0.417
mmol/g) in the presence of di-isopropylethylamine
(DIPEA, 4 eq) in CH2Cl2 (15 mL). The unreacted sites on
the resin were capped by washing with a mixture of
CH2Cl2/MeOH/DIPEA (17:2:1) followed by MeOH.
Following removal of the Fmoc-group using 20% pip-
eridine in N-methyl-2-pyrrolidinone (NMP), chain elon-
gation was performed with Fmoc-Gly-OH, Fmoc-
Ser(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH,
Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Thr(tBu)-OH,
Fmoc-Pro-OH, Fmoc-Pro-OH (1 mmol each), using 20%
piperidine/NMP for Fmoc deprotection, HBTU/HOBt
for activation, DIPEA as base and NMP as solvent. After
completion of the synthesis, the linear peptide was
cleaved from the resin and deprotected with CF3COOH/
water/tri-isopropylsilane (vol/vol/vol 95/2.5/2.5). Af-
ter removing the solvent, the peptide was precipitated
with diisopropyl ether (15 mL), collected by centrifuga-
tion and washed twice with di-isopropyl ether (15 mL).
Purification was performed by preparative HPLC.
HPLC analyses were performed on a Vydac (Supelco
SA, Switzerland) 218TP54 C18 column (250  46 mm;
particle size 5 m; Solvent A: H2O/TFA vol/vol 0.1%;
Solvent B: MeCN/TFA vol/vol 0.1%; flow 1 mL/min;
linear gradient A/B: from 85/15 to 45/55 in 25 min).
The retention time was estimated to 15.6 min. To
confirm the identification, MALDI-TOF MS analysis
was performed in the positive ion mode, showing an
intense peak at m/z 2401.1, corresponding to the ex-
pected monoisotopic mass of the [M  H] ion.
Stock solutions: Each peptide was dissolved in an
ammonium bicarbonate (50 mM, pH 7.5) buffer to give
a 200 M solution. Concentrations were determined by
UV at 280 nm.
Production of NCoA-1 PAS B Domain
NCOA-1 PAS B domain (residues 257–385 of human
NCoA-1) was obtained at a concentration of 30 to 50 M
in HEPES (10 mM), NaCl (150 mM), and EDTA (3.4
mM) pH 7.4 according to the protocol reported by Seitz
et al. [22]. For NanoESI experiments, the protein was
dialyzed against an ammonium bicarbonate (50 mM,
pH 7.5) buffer.
Mass Spectrometry
Mass spectrometric analysis was performed with a
hybrid quadrupole time-of-flight mass spectrometer
(Q-TOf Ultima; Waters/Micromass Ltd., Manchester,
UK) fitted with an automated chip-based nanoESI robot
(NanoMate model 100, Advion Bioscience, Ithaca, NY).
All measurements were performed in the positive ion
mode. The cone voltage was kept at 45 V and the RF
lens 1 at 100 V for all measurements. Argon was used as
collision gas and a typical setting of 10 V was used for
the collision energy parameter to optimize desolvation.
The transmission of the ions through the quadrupole
was optimized for the required mass range (m/z 1500–
3000). Mass spectra were accumulated during 2 to 3 min
to have a good signal-to-noise ratio. Calibration of the
instrument was performed using 1 M myoglobin
solution in water/methanol/acetic acid (50/50/1, vol/
vol/vol). Denaturing conditions were obtained by dis-
solving the sample in water/methanol/acetic acid (50/
50/1, vol/vol/vol), whereas nondenaturing conditions
were obtained by using an ammonium bicarbonate (50
mM, pH 7.5) buffer.
NanoESI-MS Competition Assay
Assays were carried out in a 96-well microtiter plate.
For KD measurement of [NCoA-1–cyclopeptide] com-
plex, each well was loaded with 2 L of a 30 M
NCoA-1 solution, 1 L of a 200 M peptide 2 solution,
1 L of a 50 M myoglobin solution. Peptide 1 (or
cyclopeptide) was added to a final concentration of
0–10 M (0–80 M for cyclopeptide). In each well, the
total volume was made up to 10 L by the addition of
ammonium bicarbonate buffer. The plate was incubated
at room temperature for 5 min before the NanoESI-MS
analysis. The fraction of NCoA-1 bound to peptide (2) is
correlated to the peak ratio of [NCoA-1–peptide (2)]
complex (charge state 7) versus myoglobin (charge state
8). After normalization, data were fitted with Origin
ver. 7.5 software (OriginLab Corporation, Northampton,
MA) to a sigmoid equation for IC50 values determina-
tion. The KD values were extrapolated from IC50 values
according to the method described by Nikolovska-
Coleska et al. [23].
Results and Discussion
In a first approach, we planed to use a reference peptide
with a known KD towards NCoA-1. Displacement of the
reference peptide from the protein by increasing inhib-
itor concentration should lead to a decrease of the peak
intensity of the reference [peptide–protein] complex,
and the appearance of new signals corresponding to the
[inhibitor–protein] complex. Since both reference and
sample peptides are small compared with NCoA-1, we
assumed that the ionization of the complexes should be
essentially governed by the protein. Therefore, the ratio
of peak intensities of both complexes should correlate
the relative affinities of the reference peptide and the
inhibitors towards NCoA-1.
Selection of Peptidic Reference Ligands
The interaction between STAT6 and NCoA-1 is medi-
ated by a short section of the STAT6 transactivation
domain that includes the sequence motif LXXLL (L 
leucine, X  any amino acid), which upon binding to a
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PAS-B domain of NCoA-1 folds into an amphipathic
-helix [24]. The crystal structure of a STAT6-derived
peptide (794–814) complexed with NCoA-1 PAS-B do-
main (257–385) with a 1:1 stoichiometry (PDB file 1OJ5)
was reported by Razeto et al. [25]. As reference ligands
for the competition assay, we chose two linear peptides
including residues Leu794-Gly814 (peptide 1) and Leu795-
Gly814 (peptide 2) of STAT6. Peptides 1 and 2 have an
additional C-terminal Tyr to aid concentration measure-
ments by UV. Their affinities for NCoA-1, determined
by a competitive fluorescence polarization assay and/or
isothermal titration calorimetry, have been reported to be
0.30 M and 7.5 M, respectively (Table 1) [22].
Figure 1 shows a representative spectrum of NCoA-1
in nondenaturing buffer. Two charge state distributions
are present, probably corresponding to a folded (m/z
1700–3000) and a partially or completely unfolded
conformation of the protein (m/z 800–1700). It must be
noted that the use of a denaturing buffer does not
change the charge state distribution, i.e., the protein is
quite insensitive to pH or solvent changes. In a second
experiment, NCoA-1 (6 M) was mixed in ammonium
acetate buffer (50 mM) with the two peptides (1) (Figure
2a), and (2) (Figure 2b) at a high concentration (60 M,
i.e., a 10-fold excess) compared with the protein con-
centration. Complexes (1:1 protein:ligand stoichiome-
try) were only observed for the charge states 7 and 8,
whereas no complex was observed in the m/z 800–1700
range. This confirmed that charge states 6, 7, and 8
correspond to the folded active protein, whereas the
higher charge states correspond to inactive conforma-
tions. In the case of peptide (1) (Figure 2a), only a very
weak signal at m/z2800 was found for the 7 complex
that corresponds to a 1:2 protein:ligand stoichiometry.
Since we showed by isothermal titration calorimetry
(ITC) that peptide (1) binds to NCoA-1 in a 1:1 interac-
tion model [22], we assumed that the 7 complex only
results from gas-phase interactions due to the high
concentration of the ligand. This has been confirmed at
lower peptide concentration (ratio 1:5 or below) by the
disappearance of the signal corresponding to the 1:2
protein:ligand stoichiometry complex.
Figure 1. NanoESI mass spectrum of NCoA-1 at a 5 M concen-
tration in a nondenaturing buffer (ammonium bicarbonate, 50
mM, pH 7.5).
Figure 2. NanoESI mass spectra of the noncovalent complexes between NCoA-1 (6 M) and (a)
peptide (1) (60 M), (b) peptide (2) (60 M), (c) peptide (A) (60 M), and (d) peptide (B) (60 M).
Filled square symbol corresponds to the ligand.
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Specific Versus Nonspecific Gas-Phase Interactions
Recently, numerous cyclopeptide competitive inhibitors
of STAT6–NCoA-1 binding were developed in Robin-
son’s group. KD values of the [NCoA-1–cyclopeptide]
complex have been measured by a competitive fluores-
cence polarization assay [22], confirming that in solu-
tion, peptides (1) and (2) and all the inhibitors interact
with the same binding site on NCoA-1 PAS-B domain.
Three cyclopeptide competitive inhibitors (A), (B), and
(C) have been selected for extended experiments. KD
values of inhibitors (A), (B), and (C) of NCoA-1 were
measured to be 3.0 M, 40 M, and 12.1 M, respec-
tively, by a competitive fluorescence polarization assay
[22]. Whatever the inhibitor chosen, at 6 M protein and
60 M cyclopeptide concentrations, complexes with 1:1,
1:2 or even 1:3 protein:ligand stoichiometry were ob-
served for charge states 6, 7, and 8, as well for charge
state 9, which was attributed to an unfolded protein
complex (Figure 2c and d). These peaks did not disap-
pear at lower peptide concentration. We assumed that
they result from nonspecific gas-phase interactions,
probably due to direct electrostatic interactions between
deprotonated carboxylate groups from glutamate resi-
dues of the cyclopeptidic inhibitors and some proton-
ated basic residues on the protein surface. Since elec-
trostatic interactions are greatly enhanced in the gas
phase compared with the solution phase (ratio of the
dielectric constant of water compared with vacuum)
[26], nonspecific electrostatic adducts are stabilized.
This assumption is first confirmed by the fact that the
nonspecific adducts resulting from the aggregation of
NCoA-1 with peptide (A) are stable even if a collision
energy parameter of 80 V (max  120 V) is applied.
Secondly, the intensity ratio between the free protein
and the aggregates is charge state dependent (Figure
2c): the higher the charge state, the higher the nonspe-
cific adducts intensity. While fluorescence polarization
competition assay showed that inhibitor (A) (KI 
3.0 M) is a tighter binder than peptide (2) (KI  7.5
M), we observed that peak intensities of [NCoA-1–
cyclopeptide (A)] complex are lower than those of
[NCoA-1–peptide (2)] complex (Figure 3). Therefore,
clearly without any quantification of the nonspecific
gas-phase interactions, no direct results on the relative
KD can be obtained.
To estimate the nonspecific binding, we first focused
on the methodology developed by Klassen et al. [16],
consisting on the analysis of noncovalent complexes,
which result only from gas-phase interactions between
a ligand and a model protein. The principal assumption
is that the peak distribution of complex resulting from
nonspecific interactions should proceed independently
from the size and the structure of the protein (NCoA-1
and the model protein). Therefore, we mixed inhibitor
(B) (60 M) with three different reference model pro-
teins (myoglobin, lactalbumin, or lysozyme at 6 M
final concentration). Inhibitor (B) was chosen as a test
compound because of its very low affinity for NCoA-1
Figure 3. NanoESI spectrum of the noncovalent complexes be-
tween NCoA-1 (6 M), peptide (A) (20 M) and peptide (2) (20
M). Filled triangle and filled square correspond to the peptides
(A) and (2), respectively.
Figure 4. NanoESI spectra of the nonspecific noncovalent complexes between (a) myoglobin (6 M),
(b) lactalbumin (6 M), or (c) lysozyme (6 M) and peptide (B) (60 M). Filled square corresponds to
the ligand.
307J Am Soc Mass Spectrom 2009, 20, 303–311 NONSPECIFIC NONCOVALENT INTERACTIONS IN ESI-MS
(KD  40 M determined by fluorescence polarization)
in solution. Figure 4 shows the results obtained for
myoglobin, lactalbumin, and lysozyme (Figure 4a, b,
and c, respectively). For myoglobin (MW17,600 Da)
and lactalbumin (MW14,200 Da), nonspecific com-
plexes were observed for the highest charge state, i.e., 8
and 7, respectively. Moreover, the intensity ratio be-
tween the free and the bound fraction of protein was
10:1 for myoglobin but only 3.5:1 for lactalbumin. For
lysozyme (MW14,300 Da), which has a molecular
weight similar to that of lactalbumin but a completely
different amino acid sequence, nonspecific complexes
were observed for the charge states 8 and 7. For the
charge state 8, we observed one or two molecules of (B)
binding to the protein, whereas only a complex with a
1:1 stoichiometry was detected for the charge state 7.
Thus, for all reference proteins, as well for NCoA-1, a
charge state dependence of the peak intensities of the
nonspecific complexes exists. Our observations suggest
that the stability of the nonspecific complexes is related
to the structure of the protein, which means that the
main assumption of Klassen et al. is not valid. Klassen’s
method was developed and validated with protein–
sugar complexes. Sugars are neutral components and
the possible noncovalent interactions with a binding
partner should only involve dipole interactions. How-
ever, for cyclopeptide (B), we have strong evidence that
electrostatic forces are involved in the nonspecific gas-
phase interactions with proteins, which apparently cre-
ates quite a different situation.
Competition Assay Using Myoglobin as
Internal Standard
To measure affinities of some noncovalent [NCoA-1–
cyclopeptide] complexes, even when ligands form non-
specific gas-phase interaction with the protein, we fo-
cused on a new competition assay consisting on the
analysis of the peak intensity of the reference [NCoA-1–
peptide (2)] complex. Since the linear peptide (2) (KD 
7.5 M) does not exhibit any nonspecific interaction
with NCoA-1, even at high concentration, we decided
to use it as reference ligand. Intensities are calibrated
with the signal of myoglobin, used as internal standard.
Myoglobin was chosen because of its very low affinity
in solution as well in gas phase for peptide (2) and for
cyclopeptides. Its concentration was fixed to 5 M.
Therefore, since formation of nonspecific complexes
with myoglobin is very limited, the peak intensity ratio
between [NCoA-1– peptide (2)] complex and myoglo-
bin should be linearly correlated to the fraction of
NCoA-1 bound to peptide (2). In a competition assay,
displacement of the peptide (2) from NCoA-1 by any
inhibitor should result in a decrease of this ratio. The
Figure 5. NanoESI spectra obtained for the competitive binding assay using the noncovalent
complex NCoA-1(6 M):peptide (2) (20 M) as probe and increasing concentration of peptide (1)
(0–10 M). Myoglobin at a 5 M concentration is used as internal standard. Filled triangles and filled
squares correspond to peptide (1) and peptide (2), respectively.
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concentration (IC50) of the inhibitor, which is required
for 50% displacement of peptide (2) from NCoA-1,
could be determined from the dependence of this
ratio on inhibitor concentration. Finally, the dissoci-
ation constant (KD) of the [NCoA-1–cyclopeptide]
complex could be calculated from the IC50 values
using the general Cheng-Prusoff equation described
by Nikolovska-Coleska [23].
Validation of the method was first performed on
linear peptide (1) as inhibitor, which did not show any
nonspecific interaction with NCoA-1. The concentra-
tions of peptide (2), NCoA-1 and myoglobin were fixed
at 20 M, 6 M, and 5 M, respectively. Figure 5 shows
the spectra obtained at different concentrations of pep-
tide (1) (from 0 to 10 M). Whatever peptide (1)
concentration, myoglobin did not exhibit any nonspe-
cific interactions with peptide (1) and/or peptide (2).
Since the peak intensity corresponding to the charge
state 8 of myoglobin remained similar for all samples,
the fraction of NCoA-1 bound to peptide (2) was
correlated to the peak ratio of [NCoA-1–peptide (2)]
complex (charge state 7) versus myoglobin (charge state
8). After normalization, data were plotted versus the
logarithm of peptide (1) concentration and fitted to a
sigmoid equation to determine the IC50 value (IC50 
4.2 M) (Supplemental Figure 1a, which can be found in
the electronic version of this article). KD calculated from
IC50 value was 299  20 nM, which is very close to the
KD value obtained by fluorescence polarization (KD 
260 nM) [22].
We then tested our methodology on inhibitors (A),
(B) and (C). The concentrations of peptide (2), NCoA-1
and myoglobin were fixed at 20, 6, and 5 M, respec-
tively. Each cyclopeptide gave some adducts with
NCoA-1 in 1:1 and 1:2 protein:ligand stoichiometries
(Figure 6). Nevertheless, whatever cyclopeptide concen-
trations (0 to 40 M), any nonspecific interactions with
myoglobin and [NCoA-1–peptide (2)] complex were
detected. Thus, the fraction of NCoA-1 bound to pep-
tide 2 was correlated to the peak ratio of [NCoA-1–
peptide (2)] complex versus myoglobin. After data
normalization and fitting to a sigmoidal equation, IC50
values (Supplementary Figure 2) of inhibitors (A) and
(C) were estimated to 11.3 M and 23.5 M, corre-
Figure 6. NanoESI spectra obtained for the competitive binding assay using the noncovalent
complex NCoA-1(6 M):peptide (2) (20 M) as probe and increasing concentration of inhibitor (A)
(0–40 M). Myoglobin at a 5 M concentration is used as internal standard. Filled triangles and filled
squares correspond to inhibitor (A) and peptide (2), respectively.
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sponding to KD values of 2.2 M and 5.6 M, respec-
tively. These values are in good agreement with fluo-
rescence polarization measurements (KD  3 and 12.1
M, respectively). For inhibitor B, we also confirmed its
low affinity for NCoA-1 (KD  20 M).
By using peptide (2) as reference compound, we
were able to determine KD values from 0.1 to 20 M that
showed a very good correlation with liquid phase
measurements. However for a stronger ligand, another
reference compound would have to be chosen. To
extend the affinity range that we can measure, we
propose to use peptide (1) (KD  299 nM) as reference
peptide. Validation of this new probe was done with
the N-acetylated linear peptide (6) that includes resi-
dues Gly783-Gly814 of STAT6, as competitor. The con-
centrations of peptide (1), NCoA-1 and myoglobin were
fixed at 20, 6, and 5 M, respectively. After data
normalization and fitting to a sigmoid equation (Sup-
plemental Figure 1B), the IC50 values of peptide (6) was
estimated to be 4 M, corresponding to a KD of 17 nM,
which is again in good agreement with reported fluo-
rescence polarization data (KD 40 nM) [22]. It must be
noted that such low KD values that are lower than 2 to
3 orders of magnitude of the concentrations used in
experiments are usually difficult or impossible to mea-
sure by direct titration using nanoESI-MS [27].
Conclusions
The potential of mass spectrometry for direct analysis of
complex biological samples has been extensively dem-
onstrated. In particular, because of its high sensitivity
and selectivity, nano-ESI MS becomes a real alternative
for quantitative analysis and monitoring [protein–
ligand] binding. However, the study of protein–ligand
noncovalent complexes requires careful control of ex-
perimental parameters since desolvation/ionization
mechanisms involved in ESI can complicate the analy-
sis. We reported in the present study a new nano-ESI
MS competition assay, which is of value to determine
the affinity of weak protein–ligand complexes, even
when nonspecific electrostatic interactions are exhibited
in gas phase. The measurement of KD values, in good
agreement with results obtained by an independent
fluorescence polarization assay, confirms that when the
reference ligand and the internal standard are properly
selected, the method can be implemented for many
different types of noncovalent complexes. Finally, au-
tomation of sample preparations and data acquisition
should allow accessing to a medium or even high-
throughput screening assay to find inhibitor of [protein–
protein] interaction.
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